Neovacs in Paris (France) investigates immunotherapies for the treatment of autoimmune diseases and today signed a partnering agreement with the molluscan protein manufacturer, Stellar Biotechnologies (US).
This joint venture will operate under the name of Neostell SAS, and it will be owned 30:70, the majority going to Neovacs. Neovacs is a biotech focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and (or) inflammatory diseases.
KLH is used as both a finished product for measuring immune status, as well as the active pharmaceutical ingredient (API) in a wide range of immunotherapies (targeting cancer, immune disorders, Alzheimer’s, and inflammatory diseases).
We met the CEO of Neovacs, Miguel Sieler, at BIO-Europe in November. Sieler explained how their Kinoids are used to stimulate a polyclonal antibody response to a specific cytokine used (depending on the indication targeted).
For example, one immunotherapy using Stellar’s limpet proteins is Neovacs’ IFNα-Kinoid – a ‘conjugate vaccine’ being developed for the debilitating autoimmune disease, Lupus erythmatosus (and dermatomyositis).
Lupus is a huge area of unmet medical demand, and you can read more about who in the field is struggling to develop a therapy for it in our brief review.
The investment in this production will begin after receiving positive results of the phase IIb study with IFNα-Kinoid in Lupus, which is currently under way. The site of Neostell will also be close to Paris, and is expected to hire between 50 and 100 high-qualified employees by midterm.
This is an innovative, and potentially huge development in the work towards a vaccine against autoimmune diseases…we eagerly await these phase IIb results!